Skip to main content
Fig. 2 | Molecular Neurodegeneration

Fig. 2

From: Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy

Fig. 2

Neither tau antibody led to benefits in a fear conditioning test or affected motor performance. a–j Treatment benefits were not observed in a fear conditioning test for a 4E6 or b 6B2, which relies on different brain circuits than the navigational test, or in motor tests (c-j), which were performed to verify that the cognitive benefits cannot be explained by confounding changes in motor performance. As expected, mice from both treated and control groups generally performed better on their post-treatment motor tests because of their pre-treatment training. *: p < 0.05, **: p < 0.01, ***: p < 0.001. Stm: Short-term memory, Ltm: Long-term memory

Back to article page